Alzheimer's Breakthrough: Lithium Reverses Memory Loss in Mice
Led by a team from Harvard Medical School, the researchers wanted to investigate previous links that have been made between exposure to metals and dementia risk.
Through hundreds of donated brain tissue and blood samples taken from people with advanced Alzheimer's, early-stage mild cognitive impairment (MCI), and no cognitive issues at all, the team ran tests for dozens of different metals.
Related:
Only one metal showed significant differences in abundance between these groups: lithium. Reduced levels of this metal were also noticeable at the earliest stages of memory loss in the tested samples.
"The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach," says geneticist and neurologist Bruce Yankner, from Harvard Medical School.
While lithium is widely used to treat bipolar disorder, this is the first time it's been found to be naturally present in the brain.
"Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C," says Yankner. "It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug."
Further analysis revealed that the amyloid-beta protein clumps that accompany Alzheimer's seemed to be binding to lithium in the brain, making less of it available to neurons and further accelerating the progression of the disease.
Next, the researchers ran tests on mice, finding that depriving their brains of lithium dramatically increased the clumps of amyloid-beta in their brains. The amount of another Alzheimer's-related protein called tau also increased.
Even better, the researchers found that a certain type of lithium, lithium orotate, could evade capture by amyloid-beta proteins. When small doses of it were given to mice with Alzheimer's-like symptoms, the animals' memory function was restored, and other signs of cognitive decline were effectively reversed.
There are still plenty of questions left unanswered, as is often the case with Alzheimer's, which is an incredibly complex disease. At the moment, it's not clear how levels of lithium begin to drop, for example, and how that then leads to signs of dementia.
Further studies should help to clarify that, and clinical trials are the next significant step. Eventually, Alzheimer's could be diagnosed earlier by measuring patients' lithium levels, while lithium supplements could be a useful preventative or treatment.
With the number of people with dementia on the rise, there's an urgent need to find ways of protecting the brain against the devastating consequences of the condition.
"You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial, but so far the results are very encouraging," says Yankner.
The research has been published in Nature.
Related News
A Routine Vaccine May Lower Dementia Risk by as Much as 20%
Just One High-Fat Meal Can Disrupt Blood Flow to Your Brain, Study Finds
Scientists Discover a Viral Cause of One of The World's Most Common Cancers
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
10 minutes ago
- Yahoo
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio


Medscape
42 minutes ago
- Medscape
Canadians Launch Country's First Black Medical Journal
The launch of Canada's first Black medical journal has been welcomed by the Black community as a major step towards promoting diversity in healthcare research. The Nigerian Canadian Medical Journal was launched on August 2 in Edmonton by the Canadian Association of Nigerian Physicians and Dentists (CANPAD). Hadal El-Hadi, MD 'This new journal can make a significant difference in addressing the health and social issues faced by Black Canadians,' Hadal El-Hadi, MD, founder of Black Physicians of Canada, told Medscape Medical News. 'By providing a dedicated platform for research, scholarship, and dialogue, it can elevate the voices of Black scholars and practitioners.' El-Hadi, who is not involved in the journal, added that it could further play a role in highlighting critical health disparities, promoting culturally relevant research, fostering interdisciplinary collaborations, and serving as a resource to guide the development of effective interventions and strategies that are tailored to the unique needs of Black communities. Journal to Fill Minority Gaps in Research The journal's editor-in-chief, Moses Ademola, MD, explained to Medscape Medical News that the aim was to create a peer-reviewed, open-access publication that provides fresh insights and a new global perspective that appeals to readers within and beyond the Nigerian community. 'We know from working around different teams that a diverse team improves outcomes for our patients, who, increasingly, are coming to us in diverse forms,' said Ademola, who is an emergency physician at Sturgeon Community Hospital, St. Albert, Alberta, and Royal Alexandra Hospital in Edmonton. 'The CANPAD journal was formed to enrich medical discourse, offer mentorship, and foster collaborative research. While the journal is published by a Black committee, it's aimed at a broad global audience. It's our hope and prayer that it will reflect the multicultural and inclusive values of Canada. We'll follow the science and go where we feel we can make a difference. We want to be a platform for voices that would otherwise be missed,' Ademola explained. Black Canadians Face Health Inequities A Government of Canada public health agency study published in 2020 reported that racism has been increasingly recognized as an important driver of inequitable health outcomes for visible minority Canadians. 'The healthcare challenges faced by Black Canadians are distinct due to historical factors, including the legacy of colonialism and systemic racism, which create unique barriers to care,' said El-Hadi. 'Black patients can experience discrimination within healthcare settings, leading to mistrust and inadequate treatment. Additionally, cultural differences in health perceptions and the stress from ongoing racism contribute to disparities in health outcomes,' she said. Lack of inclusion and diversity continues to be a source of concern for the Black community and public health organizations. 'Research gaps and health inequalities exist, and some of these are not modifiable,' explained Ademola. 'The Irish population tends to have cystic fibrosis. Blacks have a disproportionately high incidence of sickle cell disease. And Ashkenazi Jews are enriched for carriers of a fatal form of Tay-Sachs disease.' If clinicians aren't equipped to manage them well, the outcomes tend to be poorer, he said. El-Hadi said there is a need for focused research on chronic diseases within Black communities, particularly concerning the impact of racism and stress. Historically, the Black population in Canada and globally has been underrepresented in clinical research in terms of participation in clinical trials, as researchers, and in access to funding. Health studies often lack sufficient representation of Black Canadians, limiting understanding of their specific health needs. Cultural differences in health behaviors are also often overlooked, skewing data applicability. 'The medical community will have to work harder to ensure we don't end up with an unintended racial bias. The government must be intentional in ensuring that equity gaps are bridged. Scholars and scientists everywhere have to be aware of this blind spot. We need to work together so that health outcomes in all our population are similar,' said Ademola. Canada's Social Sciences and Humanities Research Council developed a work plan in 2020 to address anti-Black racism in research, leading to the establishment of an external advisory committee of Black researchers. The council says it aims to ensure that Black researchers have fair access to research support and is working with stakeholders to advance their equitable participation in the research ecosystem. Ademola and El-Hadi reported having no relevant financial relationships.
Yahoo
an hour ago
- Yahoo
Ben Askren Reveals What Awakened in Him After His 45-Day Coma
Ben Askren Reveals What Awakened in Him After His 45-Day Coma originally appeared on Athlon Sports. Ben Askren opens up after dying four times and waking from a 45-day coma The combat sports world has seen its share of comebacks—but none like this. After a 45-day coma, multiple cardiac arrests, and a life-saving double lung transplant, former UFC star Ben Askren has returned home and broken his silence. The 41-year-old revealed that he flatlined not once, but four times while battling a severe staph infection that left him on life support. What followed wasn't just a physical transformation—it was a spiritual one. In a clip shared by Happy Punch, Askren confirmed that he woke up from his coma with a newfound faith after 15 years of denying Christianity. 'I woke up and I started as a Christian. I hadn't gone with my wife to church for 15 years—that was part of the deal. I said, 'I'm not a Christian, but I will support you.' When I woke up, I knew I had to do it.' he revealed in an emotional video posted to social media. He's now focused on recovery after spending 59 days in the hospital—but the journey has taken another turn. Askren is currently back in the hospital following concerns over a suspected chest tube infection, as reported by Yahoo Sports. He's receiving antibiotics and undergoing additional imaging to monitor the situation. While it's a discouraging setback, Askren has remained positive, acknowledging that healing isn't always a straight line and expressing hope to be back home soon. Askren's battle isn't over—but his second act is just beginning. With each step forward and every obstacle faced, he continues to show the same resilience that once made him a champion in the cage—only now, the fight is for something far greater than a title. This story was originally reported by Athlon Sports on Aug 7, 2025, where it first appeared.